LAT Co.,Ltd. (XKON:311060)

Verve Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2017	FY 2016
Period Ending	Dec 31, 2017	Dec 31, 2016
Operating Revenue	6,892	4,337
Other Revenue	-0	-
Revenue	6,892	4,337
Revenue Growth (YoY)	58.92%	-
Cost of Revenue	5,952	3,382
Gross Profit	940.79	954.57
Selling, General & Admin	481.58	500.44
Research & Development	210.1	245.06
Other Operating Expenses	38.38	30.71
Operating Expenses	762.57	805.78
Operating Income	178.22	148.79
Interest Expense	-28.58	-7.75
Interest & Investment Income	0.94	1.5
Other Non Operating Income (Expenses)	-2.39	-27.99
Pretax Income	148.19	114.56
Income Tax Expense	-	0.87
Net Income	148.19	113.69
Net Income to Common	148.19	113.69
Net Income Growth	30.35%	-
Shares Outstanding (Basic)	1	1
Shares Outstanding (Diluted)	1	1
Shares Change (YoY)	-0.26%	-
EPS (Basic)	247.00	189.00
EPS (Diluted)	247.00	189.00
EPS Growth	30.69%	-
Free Cash Flow	-27.9	-95.56
Free Cash Flow Per Share	-46.51	-158.86
Gross Margin	13.65%	22.01%
Operating Margin	2.59%	3.43%
Profit Margin	2.15%	2.62%
Free Cash Flow Margin	-0.40%	-2.20%
EBITDA	223.88	188.49
EBITDA Margin	3.25%	4.35%
D&A For EBITDA	45.66	39.7
EBIT	178.22	148.79
EBIT Margin	2.59%	3.43%
Effective Tax Rate	-	0.76%
Advertising Expenses	-	1

Source: S&P Global Market Intelligence. Standard template. Financial Sources.